Skip to Main Content

Small, low-quality biotechs burdened with weak pipelines will often design and analyze clinical trials in a way that almost guarantees executives the ability to claim victory, even if the preponderance of the data produced say otherwise.

This is the dubious feat accomplished by ResTORbio (TORC) on Wednesday with a mid-stage clinical trial of a drug for respiratory tract infections.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.